ZIVO Bioscience, Inc. (ZIVO)
| Market Cap | 16.81M -75.9% |
| Revenue (ttm) | 209.03K +164.5% |
| Net Income | -8.49M |
| EPS | -2.27 |
| Shares Out | 4.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 699 |
| Open | 4.070 |
| Previous Close | n/a |
| Day's Range | 4.050 - 4.070 |
| 52-Week Range | 1.105 - 19.650 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About ZIVO Bioscience
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and ani... [Read more]
Financial Performance
In 2024, ZIVO Bioscience's revenue was $157,220, an increase of 468.61% compared to the previous year's $27,650. Losses were -$13.38 million, 72.1% more than in 2023.
Financial StatementsNews
Zivo Bioscience announces transition to OTCID marketplace
Zivo Bioscience (ZIVO) is transitioning its common stock to quotation on the OTCID marketplace. Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026.
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
TROY, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace. Zivo Biosci...
Zivo Bioscience secures manufacturing agreement with Cyanotech
Zivo Bioscience (ZIVO) announced the signing of a manufacturing agreement with Cyanotech Corporation (CYAN) to grow, cultivate and process ZIVO’s proprietary algal biomass for its Zivolife product lin...
ZIVO Bioscience Provides Special Letter to Shareholders
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Sha...
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cu...
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
TROY, Mich.--(BUSINESS WIRE)---- $ZIVO--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietar...
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived fro...
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived fro...
ZIVO Bioscience to Present at The Microcap Conference 2025
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates...
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates...
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates...
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates...
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidate...
Zivo Bioscience downgraded to Hold from Buy at Maxim (yesterday)
Maxim yesterday morning downgraded Zivo Bioscience to Hold from Buy without a price target. The firm is positive on ZivoLife, the company’s proprietary algal biomass, and the potential to sign…
Zivo Bioscience downgraded to Hold from Buy at Maxim
Maxim downgraded Zivo Bioscience to Hold from Buy.
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product...
ZIVO Bioscience Announces Uplisting to OTCQB Market
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product...
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional prod...
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional produc...
ZIVO Bioscience Announces Reverse Stock Split
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates der...
Zivo Bioscience files to sell common stock, no amount given
17:11 EDT Zivo Bioscience files to sell common stock, no amount given
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nu...
Zivo Bioscience reports ‘positive’ results from month-long coccidiosis trial
Zivo Bioscience announced positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the company’s...
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional produc...
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritio...